Loading...
•
Sep 30, 2020
Equillium Q3 2020 Earnings Report
Announced financial results for the third quarter 2020.
Key Takeaways
Equillium reported a net loss of $6.6 million for the third quarter of 2020. They ended the quarter with $90.5 million in cash and investments, strengthened by $53.0 million in net proceeds from financings.
Reported positive response rates from the EQUATE Phase 1b trial in aGVHD patients.
Received FDA clearance to initiate the EQUINOX Phase 3 trial in hospitalized COVID-19 patients.
Presented pre-clinical data at the 2020 American College of Rheumatology (ACR) Virtual Convergence.
Raised $53.0 million in net proceeds from financings, resulting in $90.5 million in cash and investments.
Equillium
Equillium
Forward Guidance
Equillium anticipates several milestones including initiating the EQUINOX Phase 3 trial in Q4 2020 and reporting topline data from the EQUATE Phase 1b study in the first half of 2021.
Positive Outlook
- Initiate EQUINOX Phase 3 trial in Q4 2020, with initial data expected mid-year 2021.
- Report topline data from the EQUATE Phase 1b study in the first half of 2021.
- Advance the EQUALISE and EQUIP Phase 1b trials.
- Host a company-sponsored virtual Analyst Day on December 4, 2020.